New non-anti-TNF-α biological therapies for the treatment of inflammatory bowel disease

Bhavana Bhagya Rao, Abhik Bhattacharya, Gary R. Lichtenstein

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

While blockade of the tumor necrosis factor-alpha (TNF-α) pathway had been a major advancement for the treatment of inflammatory bowel disease (IBD), several additional therapeutic approaches have since been explored. Searching for novel therapeutics is important because nearly 50% of IBD patients have a poor primary response to anti-TNF agents or lose response within 12 months of therapy. Also, with better understanding of the pathophysiology of IBD, targeting alternate mechanisms of etiopathogenesis has yielded several effective medications, which may better individualize and personalize therapy in IBD. This chapter will discuss the major non-anti-TNF-α agents in the pipeline that are currently undergoing evaluation to effectively and safely treat patients with IBD.

Original languageEnglish
Title of host publicationPediatric Inflammatory Bowel Disease
PublisherSpringer International Publishing
Pages457-493
Number of pages37
ISBN (Electronic)9783031147449
ISBN (Print)9783031147432
DOIs
StatePublished - 27 Feb 2023

Keywords

  • 4SC-101
  • AJM300
  • AMG181
  • APD334
  • ATR-107
  • Abrilumab
  • Alicaforsen
  • Anti CCR9/CCL25
  • Anti IL-23
  • Anti-IL-12
  • Anti-IL-13
  • Anti-IL-17
  • Anti-IL-21
  • Anti-IL-6
  • Anti-MAdCAM-1
  • Anti-adhesion molecules
  • Anti-eotaxin-1
  • Anti-inflammatory cytokine
  • Antisense oligonucleotide
  • Apremilast
  • BL 7040
  • BMS936557
  • Bertilimumab
  • Biologic therapy
  • Blockade of JAK/STAT pathway
  • Brazikumab
  • Briakinumab
  • CCX282-B
  • CXCL10
  • Chemokine targets
  • Cobitolimod
  • Crohn disease
  • DIMS0150
  • Delmitide acetate
  • ENACT-1
  • ENACT-2
  • ENCORE
  • Eldelumab
  • Entyvio
  • Etrasimod
  • Etrolizumab
  • Filgotnib
  • Firategrast
  • GATA3DNAzyme
  • GED0301
  • GEMINI I
  • GEMINI II
  • GEMINI III
  • GEMINI LTS
  • GLPG0974
  • GSK2982772
  • Guselkumab
  • IL-10
  • IM-UNITI
  • IP-10 antagonists
  • ISIS 2303
  • Inflammatory bowel disease (IBD)
  • LT02
  • LYC-30937-EC
  • Laquinimod
  • MDX-1100
  • MLN-002
  • MLN-02
  • Mirikizumab
  • Monarsen
  • Mongerson
  • NNC0114-0006
  • Natalizumab
  • Ontamalimab
  • Ozanimod
  • PF-00547659
  • PF-04236921
  • Peficitinib
  • QAX576
  • RDP58
  • RPC1063
  • Rhu-IL-10
  • RhuMAb b7
  • Risankizumab
  • Rosiglitazone
  • SB683699
  • SHP647
  • SMAD7
  • STNM01
  • Spingosine-1-phosphate receptor modulators
  • TD-1473
  • TGF-b
  • TOP-1288
  • TRK-170
  • Tofacitinib
  • Tralokinumab
  • UNITI-1
  • UNITI-2
  • Ulcerative colitis
  • Upadicitnib
  • Ustekinumab
  • VB-201
  • Vedolizumab
  • Vercirnon
  • Vidofludimus

Fingerprint

Dive into the research topics of 'New non-anti-TNF-α biological therapies for the treatment of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this